Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Document:USA 21 CFR Part 320 09-Apr-2025: Difference between revisions

From GxPlex

Jump to: navigation, search
← Older edit
gxplex>GxPlexBot
Import from GxPlex Excel
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot)
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<noinclude>{{#set:
{{DocumentData
|DocReference=USA  21 CFR Part 320  09-Apr-2025
|DocValidityArea=USA
|DocScopes=HM
|DocName=21 CFR Part 320
|DocVersion=09-Apr-2025
|DocStatus=Current
|DocType=Legal act
|DocLanguage=EN
|DocDescription=Title 21 —Food and Drugs
Chapter I —Food and Drug Administration, Department of Health and Human Services
Subchapter D—Drugs for Human Use
Part 320 Bioavailability and Bioequivalence Requirements
https://www.ecfr.gov/current/title-21
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>
 
{{DocumentBox
|reference=USA  21 CFR Part 320  09-Apr-2025
|reference=USA  21 CFR Part 320  09-Apr-2025
|validity_area=USA
|validity_area=USA
Line 37: Line 18:
|contributors=
|contributors=
}}
}}
<noinclude>
== References ==
{| class="wikitable"
! Reference !! Scope !! Document part !! Language !! Preview
|-
| [[Reference:USA 21 CFR Part 320 09-Apr-2025 § 320.22]] || HM || § 320.22 || EN || § 320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. […]
|}
</noinclude>

Latest revision as of 14:15, 16 July 2026


Document information
Reference USA 21 CFR Part 320 09-Apr-2025
Validity area USA
Scope(s) HM
Document name 21 CFR Part 320
Version / Revision 09-Apr-2025
Status Current
Document type Legal act
Language(s) EN
Description Title 21 —Food and Drugs

Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter D—Drugs for Human Use Part 320 Bioavailability and Bioequivalence Requirements https://www.ecfr.gov/current/title-21

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors

References

 ScopeDocument partLanguagePreview
USA 21 CFR Part 320 09-Apr-2025 § 320.22HM§ 320.22EN§ 320.22 Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. […]…
Retrieved from "https://gxplex.org/index.php?title=Document:USA_21_CFR_Part_320_09-Apr-2025&oldid=20388"